Permira-Backed Company Investing in PharmaCord

Permira, the global investment firm, and PharmaCord LLC (PharmaCord), a leading provider of patient services for the pharmaceutical industry, announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord.

Founder and Chief Executive Officer Nitin Sahney and the management team will continue to lead PharmaCord and will remain significant investors in the Company alongside the Permira funds. Terms of the transaction were not disclosed.

Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of approximately €80bn and makes long-term majority and minority investments across two core asset classes, private equity and credit.

PharmaCord is a high-growth pharma services company that serves as a commercialization partner for life sciences organizations with the goal of enhancing the patient experience.

PharmaCord’s comprehensive solutions support the patient journey for specialty medications through a range of services that raise awareness, facilitate access to treatment, improve affordability and promote therapy adherence.

A leading tech-enabled player in the space, PharmaCord has relationships with over 30 pharmaceutical company clients and supports over 100 pharmaceutical products through its various programs.

As a patient services provider, PharmaCord works on behalf of drug manufacturers to simplify the patient therapeutic journey. Through a combination of its proprietary PharmaCord Lynk™ technology suite, exceptionally talented team members and its non-commercial pharmacy PharmaCord Scripts™, PharmaCord helps patients have a better experience accessing and adhering to their critical medications.

In 2023, PharmaCord announced the expansion of its operations to a new facility in Jeffersonville, Indiana. The new facility will provide additional capacity to support the continued growth in patient support programs PharmaCord administers on behalf of its life science clients. The company has been on a robust growth trajectory over the last several years, as demonstrated by this fifth facility expansion in less than five years.

PharmaCord’s new facility will seat a wide range of team members, including Benefit Specialists, Case Managers, Registered Nurses, Social Work Case Managers, Data Scientists, Software Developers, Support Services and Operational Management roles.

Recently, PharmaCord has recently expanded its executive ranks to include:

• PharmaCord announced the appointment of Cindy Padgett as Chief Commercial Officer. In her new role, Padgett will be responsible for the commercialization of corporate and client initiatives, from solution design to customer experience optimization. As Chief Commercial Officer, she will oversee Solutions Development, Quality Operations, Legal Operations and Business Optimization and Standardization.
• PharmaCord announced the appointment of Rob Brown as Chief Growth Officer. Brown, who has been a part of the PharmaCord team since June 2021 and served as the Vice President of Strategic Accounts, will now oversee the business development and marketing teams, driving strategic initiatives to accelerate PharmaCord’s growth trajectory. As Chief Growth Officer, Brown will develop and execute targeted business development initiatives, deliver innovative solutions, and further solidify PharmaCord’s position as the preferred patient services partner.